BJDX Key Statistics, Chart & Performance
The current stock price of BJDX is 0.7062 USD. In the past month the price decreased by -48.83%. In the past year, price decreased by -80.49%.
BJDX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.01 | 217.03B | ||
| ISRG | INTUITIVE SURGICAL INC | 67.03 | 204.60B | ||
| BSX | BOSTON SCIENTIFIC CORP | 32.59 | 142.51B | ||
| SYK | STRYKER CORP | 26.94 | 135.66B | ||
| BDX | BECTON DICKINSON AND CO | 13.6 | 55.98B | ||
| IDXX | IDEXX LABORATORIES INC | 54.57 | 54.95B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.58 | 50.07B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 18.17 | 37.99B | ||
| RMD | RESMED INC | 24.69 | 35.68B | ||
| DXCM | DEXCOM INC | 36.25 | 26.30B | ||
| PODD | INSULET CORP | 63.2 | 20.32B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.15 | 17.88B |
Related stock screener links
About BJDX
Company Profile
Bluejay Diagnostics, Inc. operates as a diagnostic company. The company is headquartered in Acton, Massachusetts and currently employs 7 full-time employees. The company went IPO on 2021-11-10. The company develops rapid tests using whole blood on its Symphony technology platform (Symphony), which consists of an analyzer and single-use protein detection cartridges that have the function of automatic stepwise feeding of reagent. The Symphony device is designed to produce laboratory-quality results in 20 minutes in critical care settings, including Intensive Care Units (ICUs) and Emergency Rooms (ERs). Its product candidate, the Symphony IL-6 test, is an immunoassay for the measurement of interleukin-6 (IL-6) to be used for the monitoring of disease progression in critical care settings. The company is focused on pursuing the Symphony IL-6 test in the context of sepsis. IL-6 is a clinically established inflammatory biomarker, and is considered a 'first-responder', for the assessment of severity of infection and inflammation across many disease indications, including sepsis.
Company Info
BLUEJAY DIAGNOSTICS INC
360 Massachusetts Avenue, Suite 203
Acton MASSACHUSETTS US
Employees: 7
Phone: 19786310152
BLUEJAY DIAGNOSTICS INC / BJDX FAQ
What does BLUEJAY DIAGNOSTICS INC do?
Bluejay Diagnostics, Inc. operates as a diagnostic company. The company is headquartered in Acton, Massachusetts and currently employs 7 full-time employees. The company went IPO on 2021-11-10. The company develops rapid tests using whole blood on its Symphony technology platform (Symphony), which consists of an analyzer and single-use protein detection cartridges that have the function of automatic stepwise feeding of reagent. The Symphony device is designed to produce laboratory-quality results in 20 minutes in critical care settings, including Intensive Care Units (ICUs) and Emergency Rooms (ERs). Its product candidate, the Symphony IL-6 test, is an immunoassay for the measurement of interleukin-6 (IL-6) to be used for the monitoring of disease progression in critical care settings. The company is focused on pursuing the Symphony IL-6 test in the context of sepsis. IL-6 is a clinically established inflammatory biomarker, and is considered a 'first-responder', for the assessment of severity of infection and inflammation across many disease indications, including sepsis.
What is the current price of BJDX stock?
The current stock price of BJDX is 0.7062 USD. The price decreased by -5.27% in the last trading session.
Does BLUEJAY DIAGNOSTICS INC pay dividends?
BJDX does not pay a dividend.
What is the ChartMill technical and fundamental rating of BJDX stock?
BJDX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists BJDX stock?
BJDX stock is listed on the Nasdaq exchange.
What is the market capitalization of BJDX stock?
BLUEJAY DIAGNOSTICS INC (BJDX) has a market capitalization of 1.28M USD. This makes BJDX a Nano Cap stock.
What is the ownership structure of BLUEJAY DIAGNOSTICS INC (BJDX)?
You can find the ownership structure of BLUEJAY DIAGNOSTICS INC (BJDX) on the Ownership tab.
BJDX Technical Analysis
BJDX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to BJDX. While BJDX seems to be doing ok healthwise, there are quite some concerns on its profitability.
BJDX Financial Highlights
Over the last trailing twelve months BJDX reported a non-GAAP Earnings per Share(EPS) of -33.6. The EPS increased by 97.6% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -410.48% | ||
| ROE | -543.59% | ||
| Debt/Equity | 0 |